Kubota Vision Inc. (“Kubota Vision” or the “Company”), a clinical-stage specialty ophthalmology company and a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the execution of a collaborative research agreement between Kubota Vision and China Medical University Hsinchu Hospital, Department of Ophthalmology, for a study using Kubota Glass in Taiwan, led by Dr. Ying-Shan Chen. The prospective study will evaluate the effectiveness of Kubota Glass technology in myopic children as compared with a 0.01% low-dose atropine control group, including an arm which will evaluate the potential for a synergistic effect with combination therapy.
Dr. Chen is a globally renowned leader in myopia research and treatment, serving as the chief of Ophthalmology at China Medical University Hsinchu Hospital. Dr. Chen stated, “Progressive myopia poses a heavy burden to individuals and society as a whole. I am always seeking new and effective ways to treat progressive myopic patients, so I am excited to work with Kubota Vision to evaluate Kubota Glass technology.”
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!